Tempus AI Inc (TEM) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, significant partnerships, and leadership position in a growing market make it a compelling opportunity despite short-term market volatility. The recent price pullback provides an attractive entry point for long-term investors.
The stock's MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 43.964, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting short-term weakness. Key support is at $50, with resistance at $57.644. The stock is trading near its support level, which could provide a good entry point for long-term investors.

Partnership with Merck to expand AI-driven precision medicine.
Strong revenue growth of 82.98% YoY in Q4
Leadership position in the precision oncology diagnostics market, which has a $40B TAM growing at 30% annually.
Hedge funds significantly increasing their positions, with an 884.13% increase in buying over the last quarter.
Broader market declines (S&P 500 down 0.97%).
Analysts have lowered price targets due to market volatility and valuation pullbacks.
Net income is still negative, though improving YoY.
In Q4 2025, Tempus AI reported revenue growth of 82.98% YoY to $367.2M. Net income improved significantly by 316.21% YoY to -$54.17M. EPS also improved by 275% YoY to -$0.30. Gross margin increased to 64.73%, up 6.41% YoY. These metrics highlight strong operational growth and improving financial health.
Analyst sentiment is mixed but leans positive. Recent ratings include several Buy/Outperform ratings with price targets ranging from $68 to $100. However, some analysts have expressed concerns about market volatility and valuation, leading to lowered price targets. The company's strong fundamentals and leadership position are consistently highlighted as positives.